Zohra Nooruddin, MD
Medical Oncology · San Antonio, TXNPI 1700015625
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $74,862 of the $113,421 with a category attached, or 66.0%. GSK accounts for 78.4% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $74,478, more than ten times the $3,292 reported in 2020.
Across 108 payments — averaging $1050.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$89K
- E.r. Squibb & Sons, L.L.C.$8K
- Gilead$7K
- Pharmaessentia USA Corporation$3K
- Bristol Myers Squibb$3K
- Karyopharm Therapeutics Inc.$2K
- plus $1K from 12 others
Across 17 payments — averaging $104,993 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.3M
- AstraZeneca$514K
- Takeda Pharmaceuticals U.S.A., Inc.$6K
- Incyte Corporation$1K
What the payments were for
- Consulting fees$16,33914%
- Speaking & faculty fees$74,86266%
- Travel & lodging$17,91416%
- Food & beverage$4,2644%
- Education$420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 63 | $88,965 |
| E.r. Squibb & Sons, L.L.C. | 8 | $8,273 |
| Gilead(2 entities) | 3 | $7,080 |
| Pharmaessentia USA Corporation | 3 | $3,450 |
| Bristol Myers Squibb | 7 | $2,700 |
| Karyopharm Therapeutics Inc. | 4 | $1,776 |
| AstraZeneca(2 entities) | 5 | $281 |
| ADC Therapeutics America, Inc. | 2 | $166 |
| Beone Medicines USA, Inc. | 2 | $136 |
| Genentech USA, Inc. | 2 | $131 |
| Genmab U.S., Inc. | 1 | $125 |
| Sobi, Inc | 1 | $117 |
| Beigene USA, Inc. | 2 | $82 |
| Johnson & Johnson | 1 | $35 |
| Incyte Corporation | 1 | $29 |
| Astellas Pharma US Inc | 1 | $29 |
| Blueprint Medicines Corporation | 1 | $22 |
| Novartis | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$113,421 in reported general payments places this provider in the 85th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 88 | $1,873,537 |
| OjjaaraMomelotinib Dihydrochloride | 50 | $1,494,682 |
| AyvakitAvapritinib | 27 | $1,044,950 |
| BesremiRopeginterferon Alfa-2b-Njft | 29 | $479,708 |
| VonjoPacritinib Citrate | 13 | $292,838 |
| InrebicFedratinib Dihydrochloride | 11 | $290,879 |
| ScemblixAsciminib Hydrochloride | 13 | $214,364 |
| SprycelDasatinib | 12 | $103,712 |
| Lenalidomide | 11 | $95,105 |
| PegasysPeginterferon Alfa-2a | 19 | $71,036 |
| VenclextaVenetoclax | 29 | $52,004 |
| Posaconazole | 34 | $39,614 |
| EliquisApixaban | 20 | $11,575 |
| Imatinib Mesylate | 34 | $2,461 |
| Hydroxyurea | 79 | $1,970 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $29 | $1,873,53788 claims |
| GSKOjjaara | $88,965 | $1,494,68250 claims |
| Blueprint Medicines CorporationAyvakit | $22 | $1,044,95027 claims |
| Pharmaessentia USA CorporationBesremi | $3,450 | $479,70829 claims |
| Bristol Myers SquibbInrebic | $2,700 | $290,87911 claims |
| NovartisScemblix | $22 | $214,36413 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $8,273 | $103,71212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 495 medical oncology providers in Texas.
Other medical oncology in San Antonio
- Vijay GunugantiSan Antonio$1.5M
- Virginia KaklamaniSan Antonio$787K
- John SarantopoulosSan Antonio$588K
- Sukeshi AroraSan Antonio$188K
- Anthony TolcherSan Antonio$125K
- Moshe LevyDallas$5.1M
- Suresh RatnamMcAllen$3M
- Roy HerbstHouston$1.9M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.